Pfizer (PFE) Gets a Hold from Barclays

Barclays analyst Carter Gould maintained a Hold rating on Pfizer (PFEResearch Report) yesterday. The company’s shares closed yesterday at $44.16.

According to TipRanks, Gould is a 2-star analyst with an average return of 1.1% and a 52.38% success rate. Gould covers the Healthcare sector, focusing on stocks such as Amgen, Eli Lilly & Co, and Biogen.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pfizer with a $52.64 average price target, which is a 19.20% upside from current levels. In a report released yesterday, Bank of America Securities also reiterated a Hold rating on the stock with a $50.00 price target.

See the top stocks recommended by analysts >>

The company has a one-year high of $54.46 and a one-year low of $40.72. Currently, Pfizer has an average volume of 21.88M.

Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PFE in relation to earlier this year. Most recently, in December 2022, Douglas Lankler, the EVP of PFE bought 191,862.00 shares for a total of $5,139,071.42.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Pfizer Inc. develops, manufactures and sells healthcare products, including innovative medicines and vaccines. Its key focus areas include oncology, inflammation & immunology, rare disease, vaccines and internal medicine. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Read More on PFE:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More